Evidence map›Paper›PMID 41522142›Full record

ArticleJournal of thoracic disease2025

Role of genetic alterations on outcomes for pulmonary resection in oligometastatic non-small cell lung cancer.

Zamaan Hooda, Raphael Werner, Shanique Ries, Michael Eisenberg, Wayne Hofstetter, Reza Mehran, Ravi Rajaram, David Rice, Stephen Swisher, Ara Vaporciyan and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zamaan HoodaDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Raphael WernerDepartment of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
Shanique RiesDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael EisenbergDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wayne HofstetterDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Reza MehranDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ravi RajaramDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David RiceDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stephen SwisherDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ara VaporciyanDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Garrett WalshDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Isabelle OpitzDepartment of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
Kyle G MitchellDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mara B AntonoffDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Local consolidative therapy (LCT) can improve survival outcomes for select patients with oligometastatic non-small cell lung cancer (NSCLC). While genetic alterations affect prognosis in NSCLC, their impact in oligometastatic patients undergoing lung resection as part of comprehensive LCT (cLCT) remains unclear. We sought to evaluate outcomes based on genetic alteration status in this population. Methods: We identified oligometastatic (≤3 synchronous sites) NSCLC patients from 2 centers who underwent cLCT to all disease sites from 1996-2023. Patients were stratified by genetic alteration status. Survival outcomes were evaluated with Kaplan-Meier and multivariable Cox regression models. Results: We identified 87 patients with the following genetic alterations: Conclusions:

Indexed as

Comprehensive local consolidative therapy (cLCT)genomic alterationnon-small cell lung cancer (NSCLC)oligometastatic

Identifiers

PMID41522142
PMCPMC12780397

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.